Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within 6 months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease relapsed during or within 6 months after completion of platinum-based therapy received the novel microtubule-targeting agent patupilone. Patupilone was well tolerated and demonstrated promising efficacy in this difficult-to-treat population.
Ovarian cancer is the leading cause of gynecologic-related cancer deaths in the United States. 1 The vast majority (ϳ75%) of patients present with advanced disease, which has a 5-year survival rate of only 25% to 30%. First-line treatment for advanced disease is platinumand taxane-based chemotherapy. 2 Unfortunately, more than 50% of these patients will have a relapse that is considered incurable. Those whose disease relapses either during or within 6 months after platinum and taxane therapy have a poor prognosis. Patupilone, a novel microtubule-targeting agent, is effective against both wild-type and common mutant forms of its molecular target, ␤-tubulin. It is also a poor substrate for the P-glycoprotein efflux pump, thereby overcoming key mechanisms of taxane insensitivity and resistance. Further, it is water soluble, has a long terminal half-life in the blood circulation, and shows high retention in experimental solid tumors. [3] [4] [5] [6] [7] The clinical benefit of these features has been demonstrated in solid tumors that are insensitive, resistant, and refractory to taxanes. [7] [8] [9] [10] [11] In a phase I dose-escalation study (6.5-11 .0 mg/m 2 every 3 weeks
[q3w]; N ϭ 45), patupilone demonstrated efficacy and had a manageable safety profile in patients with relapsed or recurrent ovarian cancer after taxane and platinum therapy. 12 Responses were seen at doses as low as 7.0 mg/m 2 , and the overall response rate (ORR) was 19 .4%. Stable disease (SD) was achieved in another 30.6% of patients. In the study, the maximum tolerated dose was not reached based on dose-limiting toxicities in the first cycle. The 10 mg/m 2 dose was recommended for additional studies based on adverse events (AEs) in subsequent cycles.
Here we present a phase II open-label study of the efficacy, safety, and pharmacokinetics (PK) of patupilone monotherapy (10 mg/m 2 q3w) in patients with platinum-resistant or -refractory ovarian, primary fallopian tube, or primary peritoneal cancer.
Materials and Methods

Patient Eligibility
Women 18 years of age or older with a World Health Organization performance status of 0 to 2 and histologically or cytologically documented ovarian, primary fallopian tube, or primary peritoneal cancer who had received up to 3 previous chemotherapy regimens were eligible for the study. Patients must have received a taxane/ platinum-based combination as the first-line regimen, with carboplatin greater than or equal to the area under the concentration-time curve (AUC) 5 or cisplatin greater than or equal to 75 mg/m 2 intravenously or 100 mg/m 2 intraperitoneally. Patients must have had progressive disease (PD) while receiving or within 6 months after completing at least 4 cycles of this first-line regimen. For patients who had received 2 or 3 previous regimens, the most recent regimen must have contained a platinum derivative, and progression must have occurred while the patient was receiving or within 6 months after completing the last regimen. Patients receiving consolidation therapy were permitted to enroll if they experienced documented disease progression within 6 months after the last platinum-containing therapy. Patients with measurable disease (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]) were eligible, as were those with nonmeasurable disease. For this study, patients with nonmeasurable disease were defined as those who had elevated cancer antigen 125 (CA-125) levels on at least 2 baseline measurements (1 within 7 days of the start of treatment and the other not more than 3 months before the start of treatment) and at least 1 of the following: nontarget lesions only (defined as lesions that were unidimensionally measurable with poorly defined margins), with both diameters less than or equal to 1 cm or diameters smaller than the distance between cuts, or the lesions were palpable, with either diameter less than 2 cm; malignant ascites; peritoneal carcinomatosis; or pleural effusion. Patients with an elevated CA-125 level as their only evidence of disease were not eligible for study enrollment; other exclusion criteria included peripheral neuropathy (PN) greater than Common Toxicity Criteria grade 1, unresolved bowel obstruction, and unresolved diarrhea of any grade within 7 days from the start of treatment.
The study adhered to the Declaration of Helsinki and Good Clinical Practice guidelines. Approval was obtained from each independent ethics committee and local institutional review board. All patients provided written informed consent.
Study Design
This open-label single-arm phase II multicenter study (http:// Clinicaltrials.gov: NCT00035100) was designed to assess the efficacy and safety of patupilone. The primary study endpoint was ORR, defined as the percentage of patients with a best overall response of complete response (CR) or partial response (PR) according to RECIST. Secondary endpoints included the disease control rate, defined as the percentage of patients with a best overall response of CR, PR, or SD according to RECIST; the CA-125 response rate as defined by Rustin 13 ; safety and tolerability; overall survival; PK; progression-free survival (PFS); and duration of response. 13 All enrolled patients received patupilone 10 mg/m 2 as a 20-minute intravenous infusion once q3w until disease progression or unacceptable toxicity occurred. Patients were provided with loperamide for proactive management of diarrheal symptoms according to protocol treatment guidelines. A dose-adjustment schedule was outlined in the protocol for patients experiencing unacceptable toxicity directly attributable to patupilone. The protocol called for a temporary cessation of treatment until recovery from toxicity, with continuation at the most recent dose or a 25% or 50% reduced dose, depending on toxicity grade and duration. Patients were to be removed from the study if toxicity or study drug interruption persisted longer than 3 weeks beyond the next scheduled dose according to the protocol.
Assessments
Safety assessments consisting of hematologic evaluation, blood chemistry panels, urine values, AE monitoring, vital signs, and physical examinations were conducted at screening, on day 1 of each cycle, and at the end of the study.
Target and nontarget lesions were assessed every 6 weeks by radiologic scans (computed tomography or magnetic resonance imaging). These scans were centrally reviewed by 2 independent radiologists, with a third acting as the adjudicator in case of disagreements.
PFS was measured from the date of first study treatment to the date of documented PD or death, whichever occurred first. If PD was documented beyond 13 weeks from the last tumor assessment, patients were censored at the date of the last tumor assessment. Patients without documented disease progression or death were censored at the time of the last tumor assessment before any new cancer therapy Patupilone for Platinum-Resistant Ovarian Cancer was instituted. CA-125 levels were evaluated every 6 weeks by a central laboratory. In patients with elevated CA-125 levels at baseline, PR was defined as a 50% or 75% response according to Rustin's criteria. 13 CA-125 disease progression was defined (also according to Rustin's criteria) as greater than or equal to 2 times the upper limit of normal on 2 occasions for patients who experienced a normalization of CA-125 levels or as greater than or equal to 2 times the nadir value on 2 occasions for patients whose CA-125 levels did not normalize. SD in regard to CA-125 levels was not defined, and if a patient was not determined to have PR or PD, she was classified as neither PR nor PD.
Whole blood samples were collected before dosing, at the end of dose infusion (ϳ20 minutes), and at 0.5, 1, 2, 4, 8, 24, 72, 168, 336, and 504 hours after the start of infusion. Patupilone concentrations in blood were analyzed by liquid chromatography-tandem mass spectrometry with a detection limit of 0.1 ng/mL. 13 C-labeled patupilone was used as an internal standard.
11 PK parameters were determined using a noncompartmental analysis method (WinNonlin 5.2; Pharsight, Mountain View, CA), and the AUC was calculated by a linear trapezoidal method.
Statistical Methods
The ORR was the primary efficacy variable. Several secondary efficacy endpoints, which included PFS and overall survival, were also analyzed. Responses were summarized in terms of percentage rates with 95% exact binomial confidence intervals (CIs). Time-toevent variables were analyzed using the Kaplan-Meier method. Kaplan-Meier estimates of the survival function with 95% CIs at specific time points (using Greenwood's formula for the standard error) were computed. All analyses were carried out in SAS 8.2 (SAS Institute Inc, Cary, NC).
Results
Patients
One hundred twelve patients enrolled in the study, most (92.0%) presenting with ovarian cancer (Table 1) . Although up to 3 previous regimens were permitted, 79.5% and 20.5% of patients had received 1 and 2 previous chemotherapy regimens, respectively. Most patients presented with advanced disease at their initial diagnosis (87.5% stage III/IV), and more than one-half (52.7%) of all patients had PD during or within 3 months of their last platinum treatment.
Treatment
Patients received a median of 4 cycles of patupilone (range, 1.0-16.0). The median dose per cycle was close to the planned dose of 10 mg/m 2 ( Table 2) . Dose reductions or delays because of AEs occurred in 32 patients (28.6%). Most patients (76.8% [n ϭ 86]) discontinued treatment because of disease progression. Another 13.4% (n ϭ 15) discontinued treatment because of AEs, of which 11 (9.8%) were deemed related to the study drug.
Safety
Similar to results of previous studies, diarrhea was the most common AE (31.3% grade 1, 24.1% grade 2, 22.3% grade 3, and 2.7% grade 4) ( Table 3) , which led to dose reductions or delays in 15 patients (13.4%) and discontinuation in 5 patients (4.5%). The median time to first occurrence of diarrhea (any grade) was 13.5 days (95% CI, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Complete resolution of these events (with data censored 28 days after last study drug dose if a date for return to grade 0 was not available) took a median of 4.0 days (95% CI, 3-6) for any grade and 8 days (95% CI, 5-13) for grade greater than or equal to 3. The severity of diarrhea did not increase substantially in later cycles when compared with the grade reported in the first cycle. For example, less than 5% of patients with less than or equal to grade 2 diarrhea in cycle 1 had a grade 3/4 event in cycle 3 or beyond. Nausea (62.5%), vomiting (48.2%), fatigue (42.9%), and PN (39.3%) were also common but were mild to moderate in severity. 12 patients, with only 1 (Ͻ 1%) experiencing a grade 2 event. Observed hematologic toxicities of any grade were minimal (neutropenia Ͻ 4%, thrombocytopenia Ͻ 3%), and no hypersensitivity reactions related to the study drug were reported. Of the 9 deaths that occurred during treatment or within 28 days of the last dose, none was deemed related to the study drug. Seven deaths were due to underlying disease, 1 resulted from sepsis, and another was caused by pulmonary embolism.
Pharmacokinetics
PK data, collected from 19 of the first 21 patients, showed that the patupilone blood concentration-time profile declined rapidly after intravenous infusion (Figure 1) . The large volume of distribution (1140 Ϯ 340 L/m 2 ) was consistent with the extensive tissue distribution of patupilone observed in animal models. 6 Similarly, the low blood clearance (8.9 Ϯ 3.0 L/h/m 2 ), long terminal half-life (111 Ϯ 28 hours), maximum blood concentration (102 Ϯ 53 ng/mL), and AUC (1266 Ϯ 750 ng/h/mL) were in line with the findings of previous studies. 7, 11, 12 The relationship between systemic exposure of patupilone and AEs (eg, severe diarrhea) or efficacy could not be assessed conclusively because of the small size of the PK analysis set.
Efficacy
Based on the central radiologic review, the best overall response according to RECIST observed in the total patient population (N ϭ 112) was PR in 7 patients, which equaled an ORR of 6.3% (95% CI, 2.6%-12.5%) ( Table 4 ). An additional 50 patients (44.6%) had SD as their best overall response according to RECIST (Table 4) , resulting in a disease control rate (CR ϩ PR ϩ SD) of 50.9% (95% CI, 41.3%-60.5%). Median PFS was 2.8 months (95% CI, 2.0-3.2 months) and median overall survival was 11.2 months (95% CI, 8.3-14.9 months) (Figure 2) , with a 1-year overall survival rate of 48.4%. The median duration of disease control was 5.4 months (95% CI, 4.2-5.8 months). Similar disease control rates were observed in patients for whom the sum of the longest diameter of the measurable target lesions was less than or equal to 5 cm and greater than 5 cm at baseline (46.4% and 47.8%, respectively).
In an exploratory analysis, CA-125 response according to Rustin criteria 13 was assessed for the 72 evaluable patients with elevated CA-125 levels at baseline. PR in regard to CA-125 levels was con- 
Discussion
Women with ovarian cancer that progresses within 6 months after a platinum-and taxane-containing regimen have a poor prognosis. Clinical trials in this patient population demonstrate limited efficacy of chemotherapy and poor survival outcomes, highlighting the need for additional treatment options. In this phase II study, patupilone 10 mg/m 2 q3w achieved a disease control rate of greater than 50%.
Although it is unclear why the ORR presented here (6.3%) was lower than that reported in the phase I dose-escalation study (19.5%), the disease control rate was similar (50.9% vs. 50.0%), 12 demonstrating a signal of activity in this difficult-to-treat, platinum-resistant/refractory population. These rates are within the range observed for other single-agent studies in platinum-resistant or -refractory disease. [14] [15] [16] [17] [18] [19] [20] Upcoming analysis of the recently completed phase III study of patupilone vs. pegylated liposomal doxorubicin will more definitively characterize the activity of patupilone in this patient population. The safety profile observed in this study is consistent with results from other patupilone studies in a wide range of tumor types. 7, 9, 12, 21, 22 The most common AE, diarrhea, was predictable (median time to first occurrence was 13.5 days), generally manageable (median dose intensity was close to the planned 10 mg/m 2 ), and short in duration (events resolved to grade 0 in a median of 4.0 days). Reducing gastrointestinal toxicity through the proactive treatment and early management of diarrheal symptoms has been a key goal in patupilone development. Intriguingly, knowledge of corticosteroid control of water and electrolyte equilibrium led to a preclinical study in which prednisone administration reduced chemotherapy-induced diarrhea without impacting patupilone PK or efficacy. 23 These results are being explored in current clinical studies and suggest that further reductions in gastrointestinal AEs are feasible. Patupilone is a member of the epothilone drug class, a group of microtubule-stabilizing agents derived from the myxobacterium Sorangium cellulosum. The AE profiles of other epothilones include neutropenia and neuropathy, which are often dose limiting. [24] [25] [26] [27] [28] [29] The microtubule-stabilizing taxanes, which have demonstrated activity in platinum-resistant ovarian cancer, 16, 19 also commonly cause neutropenia and neuropathy. 30, 31 However in the present study, neutropenia was uncommon (Ͻ 4%, all grades) and PN was generally mild, with grade 3 events less than 5% (n ϭ 5) and no grade 4 events. Indeed, 3 of 5 grade 3 PN events resolved within 52 days or less. Thus the toxicity profile of patupilone is distinct from other microtubule stabilization agents both in and out of its drug class. Furthermore, unlike paclitaxel and ixabepilone, patupilone is not formulated with Cremophor (BASF, Berlin, Germany) or other similar excipients because of its relatively high water solubility. Therefore the risk of infusion-related AEs is low, and premedication to manage hypersensitivity is not required. 32 Indeed the single hypersensitivity reaction in this study was reported as not related to study drug administration. In this platinum-resistant or -refractory ovarian cancer population, patupilone at 10 mg/m 2 q3w demonstrates promising antitumor activity with a manageable toxicity profile. A phase III randomized clinical trial comparing patupilone with pegylated liposomal doxorubicin in more than 800 patients with platinum-resistant or -refractory ovarian, primary fallopian tube, or primary peritoneal cancers has recently been completed. The results of this trial, the largest ever in this patient population, will further elucidate the role of patupilone in these patients who have limited treatment options after relapse or recurrence.
Clinical Practice Points
• Approximately 75% of patients with ovarian cancer present with advanced disease, which is associated with a 5-year survival rate of only 25% to 30%.
• Patients whose disease relapses either during or within 6 months after first-line platinum-and taxane-based chemotherapy have limited treatment options and a poor prognosis.
• Patupilone is a novel microtubule-targeting agent that is effective against both wild-type and common mutant forms of ␤-tubulin.
• In a phase I dose-escalation study of patients with relapsed or recurrent ovarian cancer after taxane and platinum therapy, patupilone was associated with a manageable safety profile, an ORR of 19.4%, and an SD rate of 30.6%.
• In the present multicenter, open-label, single-arm phase II study of 112 patients with platinum-resistant or -refractory ovarian, primary fallopian tube, or primary peritoneal cancer, patupilone 10 mg/m 2 given by 20-minute intravenous infusion once q3w resulted in an ORR of 6.3%, a disease control rate of 50.9%, a median PFS of 2.8 months, a median overall survival of 11.2 months, and a 1-year overall survival rate of 48.4%. The safety profile was consistent with that observed in other patupilone studies in a wide range of tumor types, with the most common AE, diarrhea, being predictable, generally manageable, and short in duration.
• Additional data from a phase III study will further elucidate the efficacy and safety of patupilone in patients with platinum-resistant or -refractory ovarian cancer.
